TY - JOUR T1 - Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE JF - Lupus Science & Medicine JO - Lupus Sci Med DO - 10.1136/lupus-2019-000332 VL - 6 IS - 1 SP - e000332 AU - Monica M Purmalek AU - Philip M Carlucci AU - Amit K Dey AU - Maureen Sampson AU - Yenealem Temesgen-Oyelakin AU - Simantini Sakhardande AU - Joseph B Lerman AU - Alice Fike AU - Michael Davis AU - Jonathan H Chung AU - Taufiq Salahuddin AU - Zerai Manna AU - Sarthak Gupta AU - Marcus Y Chen AU - Sarfaraz Hasni AU - Nehal N Mehta AU - Alan Remaley AU - Mariana J Kaplan Y1 - 2019/07/01 UR - http://lupus.bmj.com/content/6/1/e000332.abstract N2 - Objective Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) burden to predict coronary atherosclerosis in SLE.Methods Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy.Results SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low-density lipoprotein (VLDL) particle counts compared with controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared with controls. In contrast to high-sensitivity C reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance (IR), though the association with NCB was no longer significant after adjusting for prednisone use.Conclusions Patients with SLE display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical labs, could be a useful tool in assessing CVD risk in patients with SLE. ER -